

# Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

Mahnaz Roayaei, Sedighe Ghasemi

Department of Radiation Oncology, Isfahan University of Medical Sciences, Isfahan, Iran

**Background:** Androgen deprivation is the basis of treatment for advanced stages of prostate cancer. Cardiovascular disease may be a risk factor for mortality in prostate cancer. Therefore, we decided to evaluate the effect of androgen deprivation therapy (ADT) on the cardiovascular risk factors in patients with prostate cancer. **Materials and Methods:** In a cross-sectional study on 2011, 35 patients suffering from metastatic prostate cancer as candidates for ADT were enrolled. Serum levels of fasting blood sugar (FBS), triglyceride (TG) and total cholesterol (TC) were measured at the beginning and after the 5<sup>th</sup> month of ADT. **Results:** The mean level of TG increased significantly from  $130.82 \pm 41.57$  mg/dl to  $150.05 \pm 48.29$  mg/dl ( $P < 0.012$ ). Furthermore, serum level of TC increased from  $197.62 \pm 40.71$  mg/dl to  $212.54 \pm 38.25$  mg/dl, which is statistically significant ( $P < 0.001$ ). A non-significant increase in the serum level of FBS from  $96.74 \pm 14.04$  mg/dl to  $99.17 \pm 15.23$  mg/dl was also seen ( $P = 0.27$ ). **Conclusion:** ADT in prostate cancer may lead to an increase in TG and TC levels. In patients with a high risk of cardiovascular disease patient's lipid profile should be considered during ADT.

**Key words:** Androgen antagonist, blood glucose, cholesterol, prostatic neoplasms, triglycerides

**How to cite this article:** Roayaei M, Ghasemi S. Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer. J Res Med Sci 2013;18:579-81.

## INTRODUCTION

Prostate cancer is one of the most prevalent cancers in male and the second most common cause of death due to cancer among males in the United States of America.<sup>[1,2]</sup> Men with a family history of prostate cancer are at increased risk of this disease.<sup>[3]</sup> About 86% of men who have prostate cancer are diagnosed in the localized stage. At 5 years survival of these patients is approximately 100% and 98.8% regardless of disease stage.<sup>[4,5]</sup> A great deal of mortality among these patients is not due to malignancy. Recent studies indicate that mortality from the malignancy itself is lesser than 40% in prostate cancer.<sup>[6]</sup>

Androgen deprivation therapy (ADT) is the basis of treatment for early and advanced stages of prostate cancer.<sup>[7-10]</sup> ADT in advanced localized prostate cancer increased the survival rate.<sup>[10,11]</sup>

ADT inhibits the growth of prostate tumors. In addition, it has some side-effects due to testosterone deprivation, including vasomotor symptoms, osteoporosis, anemia, gynecomastia and sexual dysfunction.<sup>[12,13]</sup> Affecting the metabolism and endocrine function of patients with prostate cancer, ADT can lead to metabolic syndrome.<sup>[14]</sup> Since much prostate cancer mortality is due to causes other than malignancy and also increased use of ADT for

its boost to survival rates, we decided to evaluate the effect of ADT on cardiovascular risk factors in prostate cancer.

## MATERIALS AND METHODS

This cross-sectional study was performed in 2011 in Seyyed-Al-Shohada hospital, Isfahan, Iran. All patients with documented metastatic prostate cancer<sup>[10]</sup> without documented cardiovascular diseases, referred for ADT to Seyyed-Al-Shohada Hospital, were included in the study. The patients were excluded from our study if they didn't follow the treatment. This project was approved by the Ethical Committee of Isfahan University of Medical Sciences (project number 290145).

After obtaining written consent from the patients, 5 cc of fasting venous blood sample was taken from each to evaluate the serum levels of total cholesterol (TC), triglyceride (TG) and fasting blood sugar (FBS) at the beginning and after 5 months of therapy. All patients received intramuscularly 3.75 mg diphereline (PharmaSwiss SA, Albania) monthly. Patients were educated for the diet considering possible effects on lipid profile changes. They were also encouraged for regular walking as well.

Data was analyzed using the Statistical Package for the Social Sciences statistics version 20 software. SPSS 20 (SPSS

**Address for correspondence:** Dr. Sedighe Ghasemi, Department of Radiation Oncology, Isfahan University of Medical Sciences, Isfahan, Iran.  
E-mail: Sg\_ghasemy@yahoo.com

**Received:** 31-05-2012; **Revised:** 05-08-2012; **Accepted:** 30-12-2012


Inc., Chicago, IL, USA) Paired *t*-tests were used for analysis. Data was considered to be significant at the level of  $P < 0.05$ .

## RESULT

A total of 35 male patients suffering from metastatic prostate cancer (Stage 4) were enrolled in this study. The mean  $\pm$  standard deviation (SD) of patient age was  $71.77 \pm 6.84$  with a range of 60-88 years old. At the beginning of the study, the mean  $\pm$  SD serum levels of FBS, TG and TC were  $96.74 \pm 14.04$  mg/dl (normal range: 65-100),  $130.82 \pm 41.57$  mg/dl (normal range  $< 200$ ) and  $197.62 \pm 40.71$  (normal range  $< 200$ ) mg/dl respectively. The mean level of TG and cholesterol was increased significantly after 5 month follow-up [Figure 1]. The patients' ages were categorized into three levels. Group A ( $n = 12$ ) were males under 70 years old, Group B ( $n = 18$ ) were males between 70 and 80 and Group C ( $n = 5$ ) were males 80 and older. Level of FBS, TC and TG were compared based on the patients' age range. In patient older than 80 years old, we don't find any significant difference in FBS, TC and TG between the beginning and end of the study [Table 1]. No mortality was observed during the 5 months follow-up.

## DISCUSSION

The result of our study indicates that the FBS level does not change significantly during the 20 weeks of treatment.



**Figure 1:** Mean of triglyceride, cholesterol and fasting blood sugar before and after intervention. TG = Triglyceride; Chol = Cholesterol; FBS = Fasting blood sugar

Other studies in this field indicate that in patients with prostate cancer who are undertaking ADT, fasting plasma insulin levels increase.<sup>[15-17]</sup> Other studies have shown that ADT may reduce insulin sensitivity.<sup>[16,18]</sup> Therefore, it is expected that fasting plasma glucose levels increase during treatment. Smith *et al.* have shown that hemoglobin A1c levels increase in ADT; however, FBS is not affected by this kind of therapy.<sup>[19]</sup> Smith's findings are in agreement with our results.

In our study results, serum levels of TG and TC increased significantly during the 5 months of ADT, which is completely in agreement with other studies.<sup>[20,16-18]</sup>

Our findings showed that cholesterol levels in patients under 70 years of age (Group A) increased the most. Furthermore, blood TG levels in patients between 70 and 80 (Group B) increased significantly ( $P < 0.05$ ). However, none of the parameters of metabolic syndrome in patients over 80 were subject to significant increase ( $P > 0.05$ ). It is possible that in men who ages over 80 years old, the level of androgen are low enough that ADT doesn't have any effect on level of androgen.

Aging reduces testicular function and thus may reduce plasma testosterone.<sup>[21]</sup> Some studies indicate that there is a significant correlation between serum testosterone levels and insulin sensitivity and that insulin injection for males suffering from hypogonadism, could maintain insulin sensitivity<sup>[22,23]</sup> and decrease insulin sensitivity over the time lead to impairing glucose tolerance.

## CONCLUSION

ADT in prostate cancer may lead to an increase in TG and TC levels. In patients with a high risk of cardiovascular disease patient's lipid profile should be considered during ADT. We suggest performing another study with a larger sample size, to compare adverse effects of ADT based on patients' age ranges.

Limitations of the study are (1) although the patients were educated for diet and exercise, the uncertainty is still present. (2) The small changes in lipid profile may be due to small sample size.

**Table 1: Comparison the level of FBS, TG and serum total cholesterol before and after treatment based on age's group**

Mg/dl	Groups A	Groups B	Groups C	P value
Level of FBS (Mean $\pm$ SD) before treatment	94.33 $\pm$ 14.15	98.33 $\pm$ 14.54	96.83 $\pm$ 14.02	>0.05
Level of FBS (Mean $\pm$ SD) after treatment	98.91 $\pm$ 12.97	101 $\pm$ 17.49	93.2 $\pm$ 12.19	
Level of TG (Mean $\pm$ SD) before treatment	140.16 $\pm$ 47.54	149.8 $\pm$ 45.27	145.27 $\pm$ 54.52	<0.05
Level of TG (Mean $\pm$ SD) after treatment	119.33 $\pm$ 34.69	150.25 $\pm$ 45.62	166.8 $\pm$ 31.79	
Level of TC (Mean $\pm$ SD) before treatment	206.83 $\pm$ 53.12	192.66 $\pm$ 33.13	204.16 $\pm$ 40.15	<0.05
Level of TC (Mean $\pm$ SD) after treatment	225.25 $\pm$ 39.16	193.4 $\pm$ 35.74		

Group A=Younger than 70 years; Group B=70-80 years; Group C=80 and older than 80; SD=Standard deviation; FBS=Fasting blood sugar; TG=Triglyceride

## REFERENCES

1. Saylor PJ, Smith MR. J Urol. 2009 May; 181(5):1998-2006; discussion 2007-8. Epub 2009 Mar 14.
2. Faris JE, Smith MR. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. *Curr Opin Endocrinol Diabetes Obes* 2010;17:240-6.
3. Sprenkle PC, Fisch H. Pathologic effects of testosterone deprivation. *Curr Opin Urol* 2007;17:424-30.
4. Leahy Y. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy. *Clin J Oncol Nurs* 2008;12:771-6.
5. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. *J Urol* 2009;181:1998-2006.
6. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome. *Cancer* 2008;112:2188-94.
7. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. *J Clin Oncol* 2004;22:2141-9.
8. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. *Cancer* 2005;103:1615-24.
9. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: A population-based cohort study. *BJU Int* 2006;98:973-8.
10. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCrocce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. *JAMA* 2004;292:821-7.
11. Roach M 3<sup>rd</sup>, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. *J Clin Oncol* 2008;26:585-91.
12. Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. *Int J Urol* 2004;11:735-41.
13. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. *JAMA* 2005;294:238-44.
14. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. *J Clin Endocrinol Metab* 2001;86:4261-7.
15. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. *J Clin Endocrinol Metab* 2006;91:1305-8.
16. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. *Clin Sci (Lond)* 2003;104:195-201.
17. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. *Urology* 2008;71:318-22.
18. Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. *J Urol* 1995;154:100-4.
19. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. *J Clin Endocrinol Metab* 2002;87:599-603.
20. Vermeulen A. Ageing, hormones, body composition, metabolic effects. *World J Urol* 2002;20:23-7.
21. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. *Diabetes Care* 2005;28:1636-42.
22. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. *J Androl* 2009;30:23-32.
23. Medlinsky JT, Napier CD, Gurney CW. The use of an antiandrogen to further investigate the erythropoietic effects of androgens. *J Lab Clin Med* 1969;74:85-92.

**Source of Support:** Nil, **Conflict of Interest:** None declared.